August, 14, 2014, Enigami Newsletter

Thanks to everyone who has signed up for Enigami Medical Cannabis subscriptions ! The first month has been fantastic.

It has been a delight to hear from everyone across the Nation. We wish you good health ! Here are a few notes about what we are up to in the next month or so.

Conferences Scheduled:

September 9, 10, 11, Enigami Medical Cannabis, LLC will be exhibiting at the Denver Medical Marijuana Professionals Conference.

Sept. 11, 2014, Enigami Medical Cannabis, LLC will be present in Minneapolis, Minnesota for a stakeholders conference at the Thompson Hall law firm offices.

Sept. 26th, Enigami Medical Cannabis, LLC will be attending and presenting at the Marijuana Tech Start Up Competition the weekend of September 26th, in Denver.

We’ll also be in attendance at the (Colorado) Marijuana Scientific Advisory Council meetings scheduled through the next few months. If you are in Denver – drop in and watch the process as Colorado decides how to research medical cannabis. Another state with an outstanding approach to medical cannabis treatment is Minnesota. Here is a link to the Minnesota regs: http://www.health.state.mn.us/topics/cannabis/faq.html#track . Minnesota’s inclusion of: “How will the state track the effectiveness and safety of medical cannabis?” and “What are the obligations of patients and health care providers participating in the state’s medical cannabis program?”… are great enhancements to the legitimacy of Dr/Pt relationships, clinical care, and serious Medical Cannabis treatment. They have good thoughts for all the state’s supporting innovations in medical cannabis treatment.

Enigami has opened up a “Ben & Jerry’s” type of competition. We are interested in proposals concerning our knowledge base which is defining the relationships between the cannabinoid combinations (or products) and the various conditions. This knowledge is largely absent from medical cannabis AND the medical field. In the future such knowledge will help educate physicians about recommending, or prescribing, medical cannabis products. It will empower Consumers. This knowledge could be used to guide product development by savvy medical cannabis product developers. It could be used to guide Federal policy, specifically the Veterans Health Administration, and State policy. Should this de-identified aggregate information be published on a Bhutanese mile marker so it may be discovered by an intrepid traveler ? Should a group of medical cannabis stakeholders decide how to disseminate the information ? Should a note be placed in a bottle and thrown out to the dark blue sea ? We’ll accept any creative proposals – even in crayon !

Sign up for the Veterans study is going gangbusters too !!! Some of you persevered through an obscure website glitch dealing with website security…THANK YOU !!!

There are downloadable Posters and Brochures available on the website: http://www.vetptsdstudy.org/ please feel free to use to “get the word out”.

Please submit any support tickets or questions to:
support@enigamisystemsinc.zendesk.com

Have you noticed the news blackout of this study – even in the medical cannabis and Veterans communities ? We’d appreciate hearing your comments on why some folk are trying to suppress medical cannabis research for Veterans with PTSD. Drop a note to us at: info@enigamisystems.com

Please “spread the word” about the Veterans study. We want to finish up the research 10,000 strong.

Scientific Study Factoid for the Day – Observational studies: going beyond the boundaries of randomized controlled trials

– Wenying Yang, Alexey Zilov, Pradana Soewondo, Ole Molskov Bech, Fawzia Sekkal, Philip D. Home (http://www.sciencedirect.com/science/article/pii/S0168822710700024)

Abstract: The term observational study describes a wide range of study designs including prospective and retrospective cohort studies, case-control studies, and cross-sectional studies, a defining feature of which is that any intervention studied is determined by clinical practice and not the protocol. Data from large, prospective observational studies provide information about the safety and efficacy of medicines in daily clinical use. Such observational studies are generally carried out once a medicine has received approval from regulatory agencies. Observational trials have inherent limitations in terms of their susceptibility to bias and confounding, restricting their ability to define causality. However, their strengths include that they reflect daily clinical practice more closely than randomized controlled trials (RCTs), both in terms of the heterogeneous patient populations that are included, and the medical interventions that they receive. Therefore, observational trials can provide clinically relevant information that is not necessarily provided by RCTs. Given the limitations of an observational study approach, it is important to optimize their study design to maximize their validity, and thus, in particular, known causes of bias and confounding should be measured. Medical investigators, health authorities, and the pharmaceutical industry all have important roles to play in designing, approving, and performing observational studies.

Comments are closed.